PURPOSE: To evaluate the feasibility and safety of intratumoral injection of an adenoviral vector encoding human interleukin-12 genes (Ad.IL-12) and secondarily, its biologic effect for the treatment of advanced digestive tumors. PATIENTS AND METHODS: Ad.IL-12 was administered in doses ranging from 2.5 x 10(10) to 3 x 10(12) viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients were thoroughly assessed for toxicity, and antitumor response was evaluated by imaging techniques, tumor biopsy, and hypersensitivity skin tests. Patients with stable disease and no serious adverse reactions were allowed to receive up to 3 monthly doses of Ad.IL-12. RESULTS: Twenty-one patients (nine with primary liver, five with colorectal, and seven with pancreatic cancers) received a total of 44 injections. Ad.IL-12 was well tolerated, and dose-limiting toxicity was not reached. Frequent but transient adverse reactions, including fever, malaise, sweating, and lymphopenia, seemed to be related to vector injection rather than to transgene expression. No cumulative toxicity was observed. In four of 10 assessable patients, a significant increase in tumor infiltration by effector immune cells was apparent. A partial objective remission of the injected tumor mass was observed in a patient with hepatocellular carcinoma. Stable disease was observed in 29% of patients, mainly those with primary liver cancer. CONCLUSION: Intratumoral injection of up to 3 x 10(12) viral particles of Ad.IL-12 to patients with advanced digestive malignancies is a feasible and well-tolerated procedure that exerts only mild antitumor effects.
PURPOSE: To evaluate the feasibility and safety of intratumoral injection of an adenoviral vector encoding human interleukin-12 genes (Ad.IL-12) and secondarily, its biologic effect for the treatment of advanced digestive tumors. PATIENTS AND METHODS: Ad.IL-12 was administered in doses ranging from 2.5 x 10(10) to 3 x 10(12) viral particles, to seven cohorts of patients with advanced pancreatic, colorectal, or primary liver malignancies. Patients were thoroughly assessed for toxicity, and antitumor response was evaluated by imaging techniques, tumor biopsy, and hypersensitivity skin tests. Patients with stable disease and no serious adverse reactions were allowed to receive up to 3 monthly doses of Ad.IL-12. RESULTS: Twenty-one patients (nine with primary liver, five with colorectal, and seven with pancreatic cancers) received a total of 44 injections. Ad.IL-12 was well tolerated, and dose-limiting toxicity was not reached. Frequent but transient adverse reactions, including fever, malaise, sweating, and lymphopenia, seemed to be related to vector injection rather than to transgene expression. No cumulative toxicity was observed. In four of 10 assessable patients, a significant increase in tumor infiltration by effector immune cells was apparent. A partial objective remission of the injected tumor mass was observed in a patient with hepatocellular carcinoma. Stable disease was observed in 29% of patients, mainly those with primary liver cancer. CONCLUSION: Intratumoral injection of up to 3 x 10(12) viral particles of Ad.IL-12 to patients with advanced digestive malignancies is a feasible and well-tolerated procedure that exerts only mild antitumor effects.
Authors: Cristhian J Ildefonso; Wesley S Bond; Azza R Al-Tawashi; Mary Y Hurwitz; Richard L Hurwitz Journal: J Biol Chem Date: 2012-08-03 Impact factor: 5.157
Authors: Daniel E Zak; Erica Andersen-Nissen; Eric R Peterson; Alicia Sato; M Kristina Hamilton; Joleen Borgerding; Akshay T Krishnamurty; Joanne T Chang; Devin J Adams; Tiffany R Hensley; Alexander I Salter; Cecilia A Morgan; Ann C Duerr; Stephen C De Rosa; Alan Aderem; M Juliana McElrath Journal: Proc Natl Acad Sci U S A Date: 2012-11-14 Impact factor: 11.205
Authors: Antonio Fontanellas; Sandra Hervás-Stubbs; Itsaso Mauleón; Juan Dubrot; Uxua Mancheño; María Collantes; Ana Sampedro; Carmen Unzu; Carlos Alfaro; Asis Palazón; Cristian Smerdou; Alberto Benito; Jesús Prieto; Iván Peñuelas; Ignacio Melero Journal: Mol Ther Date: 2010-01-19 Impact factor: 11.454
Authors: H Komita; X Zhao; A K Katakam; P Kumar; M Kawabe; H Okada; J M Braughler; W J Storkus Journal: Cancer Gene Ther Date: 2009-05-15 Impact factor: 5.987
Authors: Vladia Monsurrò; Stefania Beghelli; Richard Wang; Stefano Barbi; Silvia Coin; Giovanni Di Pasquale; Samantha Bersani; Monica Castellucci; Claudio Sorio; Stefano Eleuteri; Andrea Worschech; Jay A Chiorini; Paolo Pederzoli; Harvey Alter; Francesco M Marincola; Aldo Scarpa Journal: J Transl Med Date: 2010-01-29 Impact factor: 5.531
Authors: Sergio Lavilla-Alonso; Gerd Bauerschmitz; Usama Abo-Ramadan; Juha Halavaara; Sophie Escutenaire; Iulia Diaconu; Turgut Tatlisumak; Anna Kanerva; Akseli Hemminki; Sari Pesonen Journal: J Transl Med Date: 2010-08-23 Impact factor: 5.531